Antabuse (disulfiram) as a pilot case of nonprofit drug

International Journal of Cancer

Volumn 127, Issue 10, 2010, Pages 2486-

  Cvek, Boris ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

DISULFIRAM; GENERIC DRUG; GLUCONATE COPPER;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; GOVERNMENT; HEALTH CARE FINANCING; HUMAN; LETTER; LIVER CANCER; PATENT; PILOT STUDY; PRIORITY JOURNAL; ECONOMICS; NON PROFIT ORGANIZATION; NOTE;

DISULFIRAM; DRUG COSTS; DRUGS, GENERIC; HUMANS; ORGANIZATIONS, NONPROFIT;

EID: 78049520806     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25237     Document Type: Letter

References (5)

1. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Mates RC, Tran TB, Whaley R, Glennon RA, et al. Predicting new molecular targets for known drugs. Nature 2009; 462: 175-81.
2. Chong CR, Sullivan DJ,. New uses for old drugs. Nature 2007; 448: 645-6.
3. Boguski MS, Mandl KD, Sukhatme VP,. Drug discovery. Repurposing with a difference. Science 2009; 324: 1394-5.
4. Cvek B, Dvorak Z,. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? Drug Discov Today 2008; 13: 716-22.
5. Roin BN,. Unpatentable drugs and the standards of patentability. Texas Law Rev 2009; 87: 503-70.